1. Generics Bulletin
  2. >>Products

Teva: Our Biosimilars Strategy Has Been Fragmented, We Want To Be Global

Israeli Firm ‘Absolutely’ Believes Biosimilars Are Long-Term Growth Driver

 
• By Dean Rudge

Months into the job, Teva CEO Richard Francis delivered the company’s promise for a new dedicated strategy to return to growth. Funded by a portion of capital reallocated from Teva’s generics business to focus on innovative brands, the new strategy will continue to promote biosimilars, Teva has outlined.

Globe hands (otnaydur/Shutterstock.com)
• Source: Shutterstock

Taking a more global approach to biosimilars while leveraging the company’s vast capabilities and manufacturing scale to build out a sizeable portfolio, with a continued focus on partnerships and business development, are among plans laid out by Teva as part of the Israeli giant’s new and highly anticipated “Pivot to Growth” strategy.

Discussed with analysts during a one hour forty-five-minute call spearhead by Teva CEO Richard Francis, Pivot To Growth will see the traditional generics giant step up its focus on innovative drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products